JP2008519794A5 - - Google Patents

Download PDF

Info

Publication number
JP2008519794A5
JP2008519794A5 JP2007540588A JP2007540588A JP2008519794A5 JP 2008519794 A5 JP2008519794 A5 JP 2008519794A5 JP 2007540588 A JP2007540588 A JP 2007540588A JP 2007540588 A JP2007540588 A JP 2007540588A JP 2008519794 A5 JP2008519794 A5 JP 2008519794A5
Authority
JP
Japan
Prior art keywords
pyrimidine
benzo
furo
chloro
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007540588A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008519794A (ja
Filing date
Publication date
Priority claimed from GB0424972A external-priority patent/GB0424972D0/en
Priority claimed from EP05022665A external-priority patent/EP1776982A1/en
Application filed filed Critical
Priority claimed from PCT/EP2005/012087 external-priority patent/WO2006050965A1/en
Publication of JP2008519794A publication Critical patent/JP2008519794A/ja
Publication of JP2008519794A5 publication Critical patent/JP2008519794A5/ja
Withdrawn legal-status Critical Current

Links

JP2007540588A 2004-11-11 2005-11-11 ピリミジン化合物 Withdrawn JP2008519794A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0424972A GB0424972D0 (en) 2004-11-11 2004-11-11 Pyrimidine compounds
EP05022665A EP1776982A1 (en) 2005-10-18 2005-10-18 Pyrimidine compounds as histamine modulators
PCT/EP2005/012087 WO2006050965A1 (en) 2004-11-11 2005-11-11 Pyrimidine compounds as histamine modulators

Publications (2)

Publication Number Publication Date
JP2008519794A JP2008519794A (ja) 2008-06-12
JP2008519794A5 true JP2008519794A5 (enExample) 2008-12-25

Family

ID=35658998

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007540588A Withdrawn JP2008519794A (ja) 2004-11-11 2005-11-11 ピリミジン化合物

Country Status (6)

Country Link
US (1) US20080269239A1 (enExample)
EP (1) EP1812113A1 (enExample)
JP (1) JP2008519794A (enExample)
AU (1) AU2005303893A1 (enExample)
CA (1) CA2586316A1 (enExample)
WO (1) WO2006050965A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067433B2 (en) * 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
WO2007090854A1 (en) * 2006-02-10 2007-08-16 Cellzome (Uk) Ltd. Azetidine amino pyrimidine compounds for the treatment of inflammatory disorders
EP1860109A1 (en) * 2006-05-24 2007-11-28 Cellzome (UK) Ltd. Azetidine amino pyrimidine compounds for the treatment of inflammatory disorders
TW200815054A (en) * 2006-06-19 2008-04-01 Otsuka Pharma Co Ltd Methods of using a thiazole derivative
US7576092B2 (en) * 2006-07-11 2009-08-18 Janssen Pharmaceutica N.V. Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor
US7985745B2 (en) 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
US8735411B2 (en) 2006-10-02 2014-05-27 Abbvie Inc. Macrocyclic benzofused pyrimidine derivatives
BRPI0816922A2 (pt) 2007-09-14 2015-03-17 Janssen Pharmaceutica Nv Moduladores tieno e furo-pirimidina do receptor de histamina h4
WO2009056551A1 (en) * 2007-10-30 2009-05-07 Palau Pharma, S. A. Furo[3,2-d]pyrimidine derivatives
PE20091669A1 (es) 2007-12-21 2009-12-06 Exelixis Inc Benzofuropirimidinonas
EP2077263A1 (en) 2008-01-02 2009-07-08 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Quinazolines and related heterocyclic compounds and their therapeutic use
US8278313B2 (en) * 2008-03-11 2012-10-02 Abbott Laboratories Macrocyclic spiro pyrimidine derivatives
TW200951136A (en) * 2008-03-17 2009-12-16 Palau Pharma Sa Furo[3,2-d]pyrimidine derivatives
US8546410B2 (en) 2008-05-05 2013-10-01 Abbvie Inc. Heteroaryl-fused macrocyclic pyrimidine derivatives
PE20110061A1 (es) 2008-06-12 2011-01-31 Janssen Pharmaceutica Nv Derivados de diamino-piridina, pirimidina y piridazina como moduladores del receptor h4 de histamina
EP2201982A1 (en) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
KR20140099556A (ko) 2010-12-16 2014-08-12 에프. 호프만-라 로슈 아게 트라이사이클릭 pi3k 억제제 화합물 및 이의 사용 방법
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
CN104271579A (zh) 2012-05-03 2015-01-07 诺华股份有限公司 作为生长素释放肽受体激动剂的2,7-二氮杂-螺[4,5]癸烷-7-基衍生物的l-苹果酸盐及其结晶
EP3378476A1 (en) 2012-06-08 2018-09-26 Sensorion H4 receptor inhibitors for treating tinnitus
WO2014157599A1 (en) 2013-03-26 2014-10-02 Semiconductor Energy Laboratory Co., Ltd. Light-emitting element, compound, organic compound, display module, lighting module, light-emitting device, display device, lighting device, and electronic device
KR102287012B1 (ko) * 2014-05-28 2021-08-09 덕산네오룩스 주식회사 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
CN113707824A (zh) 2015-12-25 2021-11-26 株式会社半导体能源研究所 化合物、发光元件、显示装置、电子设备及照明装置
MX392754B (es) * 2016-05-09 2025-03-24 Biogaia Ab Seleccion de cepas bacterianas utiles en el tratamiento de la alergia.
WO2018122664A1 (en) 2016-12-28 2018-07-05 Semiconductor Energy Laboratory Co., Ltd. Light-emitting element, organic compound, light-emitting device, electronic device, and lighting device
JP2019006763A (ja) 2017-06-22 2019-01-17 株式会社半導体エネルギー研究所 有機化合物、発光素子、発光装置、電子機器、および照明装置
CN113302194A (zh) * 2019-01-04 2021-08-24 贝尔布鲁克实验室有限责任公司 作为治疗剂的cGAS活性的抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755583A (en) * 1970-06-05 1973-08-28 Chas0!nhx
JPH06220059A (ja) * 1993-01-28 1994-08-09 Tanabe Seiyaku Co Ltd 縮合ピリミジン誘導体及びその製法
JP4544820B2 (ja) * 2001-03-09 2010-09-15 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 複素環化合物
AU2003272285A1 (en) * 2002-09-06 2004-03-29 Janssen Pharmaceutica, N.V. Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
CA2542076C (en) * 2003-10-14 2013-02-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Substituted tricyclic compounds as protein kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2008519794A5 (enExample)
HRP20201539T1 (hr) Pozitivni alosterni modulatori muskarinskog m1 receptora
EP3873468A1 (en) 2-amino-n-phenyl-nicotinamides as nav1.8 inhibitors
JP2005508932A5 (enExample)
HRP20160036T1 (hr) Određeni kemijski entiteti, priprave i metode koji sadrže imidazopirimidin
JP2013515729A5 (enExample)
JP2010523556A5 (enExample)
CN106573006A (zh) 作为药物的rip1激酶抑制剂杂环酰胺
JP2011521963A5 (enExample)
HRP20161708T1 (hr) Supstituirani 4-fenil-piridini za terapiju bolesti povezanih sa nk-1 receptorom
JP2011500621A5 (enExample)
JP2009529047A5 (enExample)
EA201401150A1 (ru) Аминоиндолилзамещенные имидазолпиримидины и их применение в качестве лекарственных средств
RS52526B2 (sr) Derivati oksadiazola i njihovo korišćenje kao potencijatora metabotropnih glutamatnih receptora-842
HRP20140599T1 (hr) Derivati kiinazolin-4(3h)-ona koji se koriste kao inhibitori pi3 kinaze
JP2014511893A5 (enExample)
JP2009510044A5 (enExample)
JP2015522018A5 (enExample)
JP2016503785A5 (enExample)
JP2019505529A5 (enExample)
JP2013507426A5 (enExample)
CN100586434C (zh) 止痒剂
MX2010012189A (es) Derivados de quinuclidina como antagonistas del receptor m3 muscarinico.
Roberts et al. 4-Amino-7, 8-dihydro-1, 6-naphthyridin-5 (6 H)-ones as Inhaled Phosphodiesterase Type 4 (PDE4) Inhibitors: Structural Biology and Structure–Activity Relationships
JP2004525972A5 (enExample)